The Business Research Company The Business Research Company's Effective Pain Management Solutions Global Market Report 2025 – Market Size, ...

The global vaginal and vulval inflammatory diseases treatment market is estimated to grow from USD 3,313.3 million in 2025 to USD 5,500.7 million by 2035, recording a CAGR of 5.2% during the forecast ...

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

BURLINGAME, CA, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- Fast Melt Tablets Market is estimated to be valued at US$ 6.20 Bn in 2025 and is expected to reach US$ 11.41 Bn ...

Israel’s Teva Pharmaceutical Industries has announced that the final analysis of the pan-European PEARL Phase IV migraine ...

Israeli generics major Teva Pharmaceutical Industries has highlighted that Europe is experiencing increasing pressure on its ...

The global allergic rhinitis market is poised for substantial growth from 2025 to 2035, driven by a rise in allergic diseases, and advancements in th ...

The Global Pharmaceutical Suspension Market is valued approximately at USD 57.59 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.2% over the forecast period ...

LONDON, GREATER LONDON, UNITED KINGDOM, July 2, 2025 /EINPresswire.com/ -- The decongestants market size has shown impressive growth. Marked increase from $18.63 billion in 2024 to $20.39 billion in ...

Eli Lilly, J&J, Pfizer and Sanofi have backed a Teva lawsuit against the CMS for how it is implementing the IRA drug price negotiation program.

Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., and Sanofi presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug (TEV’574/SAR447189), a human ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.